secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-051551
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance
--------------------------------------------------------------------------------

- Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.
- Knees $788.1M (+3.4%), Hips $491.2M (-0.3%), S.E.T. $452.6M (+4.4%).
- Reiterates FY2024 guidance: constant currency revenue growth 5-6%, adjusted EBITDA $8.00-$8.15 EPS.
- FDA 510(k) clearance for ROSA Shoulder System (first robotic shoulder assist) and Z1 Femoral Hip Stem.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/zbh-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer